Roth/MKM raises Nlight stock price target on directed energy focus

Roth/MKM raised Nlight’s price target to $81 from $74 and kept a Buy rating, citing progress in the company’s shift to a pure-play directed energy laser provider. Nlight reported 2025 revenue growth of more than 70% year over year, EBITDA above $10 million at a 13% margin, and ended the year with about $162 million in backlog expected to be delivered over the next 24 months. Multiple analysts have turned constructive, with price targets ranging from $70 to $75 and the stock up 857% over the past year near its 52-week high of $74.97.

Analysis

LASR is becoming a cleaner defense-technology compounder, but the market is already pricing in a near-perfect execution path. The key second-order effect is that the company’s exit from lower-margin legacy markets should mechanically improve mix, but it also removes a stabilizing revenue base, making the equity more sensitive to program timing, budget slippage, and quarter-to-quarter contract cadence. In other words, the multiple can stay elevated only if backlog converts without a meaningful pause between HELSI-2 and the next tranche of awards.

The most important catalyst is not the current quarter itself, but whether the company can prove that directed-energy demand is becoming a repeatable procurement lane rather than a one-off program win. If new awards arrive in the next 2-3 quarters, the market may re-rate LASR as a platform supplier with multi-year visibility; if not, the stock likely transitions from story-driven momentum to valuation scrutiny. Defense revenue concentration also creates a hidden dependency on a small set of primes and budget holders, so any delay in appropriations or program reviews would hit the stock disproportionately versus broader defense peers.

The contrarian setup is that consensus is treating the defense narrative as structurally underpenetrated, but the stock’s run already discounts a lot of “future TAM” optimism. The better risk/reward may be in relative value rather than outright long exposure: LASR can outperform if program flow remains strong, but the bar for upside surprises is now materially higher than the bar for disappointment. If the first quarter marks a low point as expected, the stock can still work on a 3-6 month horizon; however, absent fresh contract catalysts, the near-term upside is probably more limited than the recent price action implies.

Key Decisions for Investors

• Trim or avoid initiating fresh outright longs in LASR after the rerating; the stock is now a momentum/expectations trade with asymmetric downside if contract timing slips over the next 1-2 quarters.
• For existing holders, consider monetizing upside via call spreads rather than stock: buy 3-6 month calls and sell higher-strike calls to stay exposed to another award-driven squeeze while capping valuation risk.
• Use LASR as a pair-trade long against a lower-beta defense name only if you want pure directed-energy exposure; otherwise prefer long quality defense primes vs short LASR on a 3-9 month horizon if you expect procurement normalization.
• Set a tactical add level only on a post-earnings pullback tied to execution, not on continued multiple expansion; the stock likely needs fresh backlog conversion evidence to justify further upside.
• Watch for any delay in new directed-energy awards or guidance comments that imply a gap after HELSI-2; that is the main trigger to reduce exposure quickly because the downside would be driven by de-rating, not fundamentals in isolation.